

Reinoud E Knops

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2764659/publications.pdf>

Version: 2024-02-01

66
papers

4,896
citations

136950

32
h-index

110387

64
g-index

67
all docs

67
docs citations

67
times ranked

2503
citing authors

#	ARTICLE	IF	CITATIONS
1	High shock impedance during subcutaneous implantable defibrillator generator replacements: Authors' reply. <i>Europace</i> , 2022, 24, 350-351.	1.7	0
2	Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial. <i>Circulation</i> , 2022, 145, 321-329.	1.6	28
3	Long-term performance of a novel communicating antitachycardia pacing-enabled leadless pacemaker and subcutaneous implantable cardioverter-defibrillator system: A comprehensive preclinical study. <i>Heart Rhythm</i> , 2022, , .	0.7	15
4	Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study. <i>European Heart Journal</i> , 2022, 43, 2037-2050.	2.2	47
5	Preclinical safety and electrical performance of novel atrial leadless pacemaker with dual-helix fixation. <i>Heart Rhythm</i> , 2022, 19, 776-781.	0.7	12
6	Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. <i>Circulation</i> , 2021, 143, 7-17.	1.6	132
7	Complications related to elective generator replacement of the subcutaneous implantable defibrillator. <i>Europace</i> , 2021, 23, 395-399.	1.7	12
8	Development and external validation of prediction models to predict implantable cardioverter-defibrillator efficacy in primary prevention of sudden cardiac death. <i>Europace</i> , 2021, 23, 887-897.	1.7	19
9	Tissues attached to retrieved leadless pacemakers: Histopathological evaluation of tissue composition in relation to implantation time and complications. <i>Heart Rhythm</i> , 2021, 18, 2101-2109.	0.7	11
10	Rationale and design of the SafeHeart study: Development and testing of a mHealth tool for the prediction of arrhythmic events and implantable cardioverter-defibrillator therapy. <i>Cardiovascular Digital Health Journal</i> , 2021, 2, S11-S20.	1.3	3
11	Accelerometer-assessed physical behaviour and the association with clinical outcomes in implantable cardioverter defibrillator recipients: A systematic review. <i>Cardiovascular Digital Health Journal</i> , 2021, 3, 46-55.	1.3	2
12	Real-world performance of the atrial fibrillation monitor in patients with a subcutaneous ICD. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 1467-1475.	1.2	4
13	Long-term follow-up of the two-incision implantation technique for the subcutaneous implantable cardioverter-defibrillator. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 1476-1480.	1.2	10
14	Subcutaneous or Transvenous Defibrillator Therapy. <i>New England Journal of Medicine</i> , 2020, 383, 526-536.	27.0	278
15	Improving the care for female subcutaneous ICD patients: A qualitative study of gender-specific issues. <i>International Journal of Cardiology</i> , 2020, 317, 91-95.	1.7	12
16	A morphology based deep learning model for atrial fibrillation detection using single cycle electrocardiographic samples. <i>International Journal of Cardiology</i> , 2020, 316, 130-136.	1.7	28
17	Evaluation of subcutaneous implantable cardioverter-defibrillator performance in patients with ion channelopathies from the EFFORTLESS cohort and comparison with a meta-analysis of transvenous ICD outcomes. <i>Heart Rhythm O2</i> , 2020, 1, 326-335.	1.7	26
18	Percutaneous leadless pacemaker implantation in a patient with bilateral venous thoracic outlet syndrome. <i>Journal of Vascular Access</i> , 2019, 20, 105-106.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Leadless pacemaker implantation after explantation of infected conventional pacemaker systems: A viable solution?. <i>Heart Rhythm</i> , 2019, 16, 66-71.	0.7	68
20	Feasibility of an Entirely Extracardiac, Minimally Invasive, Temporary Pacing System. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007182.	4.8	9
21	Leadless cardiac pacing systems: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2019, 16, 923-930.	2.8	15
22	Minimal defibrillation thresholds and the correlation with implant position in subcutaneous implantable cardioverter-defibrillator patients. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 2441-2447.	1.7	13
23	Rationale and design of the PRAETORIAN-DFT trial: A prospective randomized Comparative trial of Subcutaneous Implantable Cardioverter-Defibrillator Implantation with and without Defibrillation testing. <i>American Heart Journal</i> , 2019, 214, 167-174.	2.7	41
24	Impact of Leadless Pacemaker Therapy on Cardiac and Atrioventricular Valve Function Through 12 Months of Follow-Up. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007124.	4.8	70
25	A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score. <i>Heart Rhythm</i> , 2019, 16, 403-410.	0.7	94
26	Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials. <i>Diabetes Care</i> , 2018, 41, 1142-1148.	8.6	37
27	Six-year follow-up of the initial Dutch subcutaneous implantable cardioverter-defibrillator cohort: Long-term complications, replacements, and battery longevity. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 1010-1016.	1.7	39
28	Device orientation of a leadless pacemaker and subcutaneous implantable cardioverter-defibrillator in canine and human subjects and the effect on intrabody communication. <i>Europace</i> , 2018, 20, 1866-1871.	1.7	16
29	Successful replacement of the longest worldwide in situ Nanostim leadless cardiac pacemaker for a Micra Transcatheter Pacing System. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 51, 161-162.	1.3	12
30	Midterm Safety and Performance of a Leadless Cardiac Pacemaker. <i>Circulation</i> , 2018, 137, 633-635.	1.6	18
31	Leadless pacemaker versus transvenous single-chamber pacemaker therapy: A propensity score-matched analysis. <i>Heart Rhythm</i> , 2018, 15, 1387-1393.	0.7	35
32	Letter by Brouwer et al Regarding Article, "Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry". <i>Circulation</i> , 2018, 138, 2970-2971.	1.6	0
33	Health-related quality of life impact of a transcatheter pacing system. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 1697-1704.	1.7	20
34	The learning curve associated with the implantation of the Nanostim leadless pacemaker. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 53, 239-247.	1.3	10
35	Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies. <i>Europace</i> , 2018, 20, f240-f248.	1.7	36
36	Clinical parameters to optimize patient selection for subcutaneous and transvenous implantable defibrillator therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 990-995.	1.2	5

#	ARTICLE	IF	CITATIONS
37	Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2018, 15, 1515-1522.	0.7	123
38	Implantation of the Subcutaneous Implantable Cardioverter-Defibrillator. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, e004663.	4.8	52
39	Determinants of Subcutaneous Implantable Cardioverter-Defibrillator Efficacy. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 405-414.	3.2	69
40	J Curve in Patients Randomly Assigned to Different Systolic Blood Pressure Targets. <i>Circulation</i> , 2017, 136, 2220-2229.	1.6	42
41	Acute and 3-Month Performance of Communicating Leadless Antitachycardia Pacemaker and Subcutaneous Implantable Defibrillator. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 1487-1498.	3.2	57
42	Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry. <i>Journal of the American College of Cardiology</i> , 2017, 70, 830-841.	2.8	266
43	Multicenter Automatic Defibrillator Implantation Trial "Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. <i>American Heart Journal</i> , 2017, 189, 158-166.	2.7	31
44	Should the Subcutaneous Implantable Defibrillator Be the First Choice for Primary Prevention of Sudden Cardiac Death?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 142-144.	0.6	1
45	End-of-life Management of Leadless Cardiac Pacemaker Therapy. <i>Arrhythmia and Electrophysiology Review</i> , 2017, 6, 129.	2.4	28
46	Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2047-2055.	2.8	151
47	Algorithm-Based Screening May Improve Patient Selection for the Subcutaneous Implantable Defibrillator. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 605-614.	3.2	5
48	The learning curve associated with the introduction of the subcutaneous implantable defibrillator. <i>Europace</i> , 2016, 18, 1010-1015.	1.7	95
49	Surgical Management of Implantation-Related Complications of the Subcutaneous Implantable Cardioverter-Defibrillator. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 89-96.	3.2	21
50	Implantable cardioverter-defibrillators in adults with congenital heart disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2016, 37, 1439-1448.	2.2	101
51	Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy. <i>Heart Rhythm</i> , 2016, 13, 457-463.	0.7	46
52	Subcutaneous Implantable Cardioverter Defibrillator Lead Failure due to Twiddler Syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 1369-1371.	1.2	7
53	A leadless solution. <i>Europace</i> , 2015, 17, 800-800.	1.7	4
54	Inappropriate shocks in the subcutaneous ICD: Incidence, predictors and management. <i>International Journal of Cardiology</i> , 2015, 195, 126-133.	1.7	120

#	ARTICLE	IF	CITATIONS
55	Chronic Performance of a Leadless Cardiac Pacemaker. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1497-1504.	2.8	104
56	Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1605-1615.	2.8	458
57	Postmortem Histopathological Examination of a Leadless Pacemaker Shows Partial Encapsulation After 19 Months. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 1293-1295.	4.8	27
58	State of the art of leadless pacing. <i>Europace</i> , 2015, 17, 1508-1513.	1.7	73
59	Which Patients Are Not Suitable for a Subcutaneous ICD: Incidence and Predictors of Failed QRS-Tâ€Wave Morphology Screening. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 494-499.	1.7	117
60	Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. <i>European Heart Journal</i> , 2014, 35, 1657-1665.	2.2	410
61	Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: Implications for management. <i>Heart Rhythm</i> , 2014, 11, 426-434.	0.7	108
62	The Promise of Leadless Pacing: Based on Presentations at Nanostim Sponsored Symposium Held at the European Society of Cardiology Congress 2013, Amsterdam, The Netherlands, 2 September 2013. <i>Arrhythmia and Electrophysiology Review</i> , 2014, 3, 51-55.	2.4	5
63	Two-incision technique for implantation of the subcutaneous implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2013, 10, 1240-1243.	0.7	147
64	The Entirely Subcutaneous Implantable Cardioverter-Defibrillator. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1933-1939.	2.8	205
65	Rationale and design of the PRAETORIAN trial: A Prospective, RANdomizEd comparison of subcuTaneOus and tRansvenous ImplANTable cardioverter-defibrillator therapy. <i>American Heart Journal</i> , 2012, 163, 753-760.e2.	2.7	156
66	An Entirely Subcutaneous Implantable Cardioverter-Defibrillator. <i>New England Journal of Medicine</i> , 2010, 363, 36-44.	27.0	686